The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

Edgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dystrophy, a disease with zero approved treatments, with pivotal trial results expected Q4 2026. The stock has tripled from its 52-week low and faces two binary catalysts this year.

BridgeBio Pharma stock surged 12.60% following William Blair's initiation of coverage with an Outperform rating and $93.03 price target. The analyst highlighted the company's accelerating Attruby launch, near-term NDA submissions for disease-modifying therapies, and a strong pipeline in rare genetic diseases including achondroplasia and autosomal dominant hypocalcemia. BridgeBio's products are positioned as next-generation alternatives to Pfizer's market-leading tafamidis.

Tenaya Therapeutics shares surged 31.20% following a research collaboration agreement with Alnylam Pharmaceuticals focused on discovering genetic targets for cardiovascular disease treatments. Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments with potential milestone payments reaching $1.13 billion. Despite the positive news, the stock remains in a bearish trend trading below its 100-day and 200-day moving averages.

The global amyloidosis therapeutics market is experiencing strong growth, valued at $2.95 billion in 2024 and expected to reach $6.37 billion by 2033 with a 9.20% CAGR. Growth is driven by accelerating ATTR cardiomyopathy diagnosis through imaging technologies, rapid uptake of disease-modifying therapies in North America, and expanded reimbursement in emerging markets like China and Brazil. Five core compounds dominate the market, with chemotherapy remaining the cost-effective backbone for AL amyloidosis treatment.

Alnylam Pharmaceuticals announced its 'Alnylam 2030' five-year roadmap, targeting durable global leadership in transthyretin (TTR) diseases with plans to launch nucresiran by 2028-2030. The company projects 2026 net product revenue of $4.9-5.3 billion (71% growth), significantly above Street estimates, with TTR franchise expected to reach $4.4-4.7 billion. However, shares fell 10% on Monday despite strong guidance, as 2025 revenues narrowly missed expectations.

Scenic Biotech announced a license and research agreement with Ono Pharmaceutical to utilize its Cell-Seq platform for discovering novel therapeutic targets. This marks Scenic's fourth major pharmaceutical collaboration, joining existing partnerships with Genentech, Bristol Myers Squibb, and Alnylam.

Vertiv Holdings, an AI infrastructure company providing data center power and cooling solutions, has a 71% probability of being added to the S&P 500 in Q1 2026 according to prediction markets, significantly higher than competitors. The company has surged over 1,047% in less than three years with strong financial performance, including 29% year-over-year revenue growth and a robust $9.5 billion backlog.

Nasdaq announced its annual Nasdaq-100 Index reconstitution, adding six companies and removing six others, effective December 22, 2025. The changes reflect the dynamic composition of leading non-financial companies across various sectors.

Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.

Alnylam Pharmaceuticals reported strong Q3 earnings, beating analyst expectations with a 149% year-over-year sales increase and raised fiscal 2025 sales guidance. The company showed promising results for its drug Amvuttra in treating transthyretin amyloid cardiomyopathy.